1-20 of 33
Jing-Zhou Hou
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Escalating Doses of AZD0486, a Novel CD19xCD3 T-Cell Engager, Result in High Complete Remissions with Rapid Clearance of Minimal Residual Disease in Patients with Relapsed/Refractory Follicular Lymphoma

Jing-Zhou Hou, Ranjit Nair, Ryan Jacobs, Tae Min Kim, Seok-Goo Cho, Dai Maruyama, Sumana Devata, Yazeed Sawalha, Dok Hyun Yoon, Constantine S. Tam, Koji Izutsu, Matthew Matasar, Don A. Stevens, Aravind Ramakrishnan, Denise Brennan, Xu Zhu, Robin Lesley, Yasuhiro Oki, David Sermer, Sameh Gaballa
Journal: Blood
Blood (2024) 144 (Supplement 1): 341.
https://doi.org/10.1182/blood-2024-193589
Published: 2024
Journal Articles

Real-World Bruton Tyrosine Kinase Inhibitor (BTKi) Utilization and Clinical Outcomes Among Patients with Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

Jing-Zhou Hou, Rushir Choksi, Gregory A. Maglinte, Anupama Vasudevan, Anna Rui, Brandon Wang, Hoa Pham, Ann Lasn, Simon Blanc
Journal: Blood
Blood (2024) 144 (Supplement 1): 2353.
https://doi.org/10.1182/blood-2024-207760
Published: 2024
Journal Articles

Treatment-Emergent Cardiovascular Events Among Patients with Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) Treated with Bruton's Tyrosine Kinase Inhibitors (BTKi)

Jing-Zhou Hou, Rushir Choksi, Anupama Vasudevan, Anna Rui, Poras Davé, Mike Gart, Brandon Wang, Prateesh Varughese, Simon Blanc
Journal: Blood
Blood (2024) 144 (Supplement 1): 3253.
https://doi.org/10.1182/blood-2024-199765
Published: 2024
Journal Articles

Evaluation of AZD0486, a Novel CD19xCD3 T-Cell Engager, in Relapsed/Refractory Diffuse Large B-Cell Lymphoma in an Ongoing First-in-Human Phase 1 Study: High Complete Responses Seen in CAR-T-Naive and CAR-T-Exposed Patients

Sameh Gaballa, Jing-Zhou Hou, Sumana Devata, Seok-Goo Cho, Ranjit Nair, Dok Hyun Yoon, Ryan Jacobs, Koji Izutsu, Don A. Stevens, Dai Maruyama, Constantine S. Tam, Yazeed Sawalha, Aravind Ramakrishnan, Matthew Matasar, Denise Brennan, Sue Zhu, Robin Lesley, Yasuhiro Oki, David Sermer, Tae Min Kim
Journal: Blood
Blood (2024) 144 (Supplement 1): 868.
https://doi.org/10.1182/blood-2024-193681
Published: 2024
Journal Articles

Assessing Adoption of Standard of Care and Comparing Clinical and Demographic Differences in First-Line (1L) Treatment (Tx) of Chronic Lymphocytic Leukemia (CLL)

Jing-Zhou Hou, Michael Gart, Anupama Vasudevan, Harvey I. Katzen, Rushir Choksi, Simon Blanc
Journal: Blood
Blood (2023) 142 (Supplement 1): 130.
https://doi.org/10.1182/blood-2023-178685
Published: 2023
Journal Articles

Outcomes in Chemotherapy-Ineligible Elderly Patients with Newly Diagnosed Acute Myeloid Leukemia Treated with Venetoclax Plus Azacitidine: A Pooled Analysis

Adriano Venditti, Jing-Zhou Hou, Pierre Fenaux, Brian A. Jonas, Radovan Vrhovac, Pau Montesinos, Jacqueline S. Garcia, David Rizzieri, Michael J Thirman, Stanley Kotey, Jalaja Potluri, Mazaher Dhalla, Vinod Pullarkat
Journal: Blood
Blood (2023) 142 (Supplement 1): 2886.
https://doi.org/10.1182/blood-2023-182045
Published: 2023
Journal Articles

Double Step-up Dosing (2SUD) Regimen Mitigates Severe Icans and CRS While Maintaining High Efficacy in Subjects with Relapsed/Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (NHL) Treated with AZD0486, a Novel CD19xCD3 T-Cell Engager (TCE): Updated Safety and Efficacy Data from the Ongoing First-in-Human (FIH) Phase 1 Trial

Sameh Gaballa, Ranjit Nair, Ryan W Jacobs, Sumana Devata, Seok-Goo Cho, Don A. Stevens, Dok Hyun Yoon, Nirav N. Shah, Denise Brennan, Jason Law, Robert Chen, David Sermer, Robin Lesley, Ben Buelow, Alessandra Forcina, Jing-Zhou Hou
Journal: Blood
Blood (2023) 142 (Supplement 1): 1662.
https://doi.org/10.1182/blood-2023-174668
Published: 2023
Journal Articles

Real-World Bruton Tyrosine Kinase Inhibitor (BTKi) Treatment Patterns Among Patients with Chronic or Small Lymphocytic Leukemia (CLL/SLL) in US Community Oncology Practices

Jing-Zhou Hou, Simon Blanc, Gregory A Maglinte, Anupama Vasudevan, Anna Rui, Michael Gart, Hoa Pham, Lindsay Aton, Brandon Wang, Rushir Choksi
Journal: Blood
Blood (2023) 142 (Supplement 1): 5163.
https://doi.org/10.1182/blood-2023-174915
Published: 2023
Journal Articles

Long-term follow-up of VIALE-C in patients with untreated AML ineligible for intensive chemotherapy

Clinical Trials & Observations
Andrew H. Wei, Panayiotis Panayiotidis, Pau Montesinos, Kamel Laribi, Vladimir Ivanov, Inho Kim, Jan Novak, Rebecca Champion, Walter Fiedler, Maria Pagoni, Julie Bergeron, Stephen B. Ting, Jing-Zhou Hou, Achilles Anagnostopoulos, Andrew McDonald, Vidhya Murthy, Takahiro Yamauchi, Jianxiang Wang, Qi Jiang, Yan Sun, Brenda Chyla, Wellington Mendes, Courtney D. DiNardo
Journal: Blood
Blood (2022) 140 (25): 2754–2756.
https://doi.org/10.1182/blood.2022016963
Published: 2022
Includes: Supplemental data
Journal Articles

Trial-in-Progress: A Phase 2 Study of Mitoxantrone, Etoposide and Gemtuzumab Ozogamicin (MEGO) for Acute Myeloid Leukemia That Persisted after the 1 st Induction Regimen

Konstantinos Lontos, Robert L. Redner, Mounzer Agha, Anastasios Raptis, Jing-Zhou Hou, Rafic J. Farah, Annie Im, Kathleen Dorritie, Alison R. Sehgal, James M. Rossetti, Daniel Normolle, Michael M. Boyiadzis
Journal: Blood
Blood (2022) 140 (Supplement 1): 6145–6146.
https://doi.org/10.1182/blood-2022-156468
Published: 2022
Journal Articles

Application of a Validated Composite Comorbidity Score Measuring Both Fitness and Cytogenetic Risk to Assess Outcomes in 1L AML Patients Who Received Venetoclax Plus Azacitidine in Viale-A

Adriano Venditti, Jing-Zhou Hou, Pierre Fenaux, Brian A. Jonas, Radovan Vrhovac, Pau Montesinos, Jacqueline S. Garcia, David Rizzieri, Michael J. Thirman, Melissa Montez, Yingyi Liu, John Katsetos, Jalaja Potluri, Catherine Miller, Vinod A. Pullarkat
Journal: Blood
Blood (2022) 140 (Supplement 1): 8993–8995.
https://doi.org/10.1182/blood-2022-158500
Published: 2022
Journal Articles

Interim Results of the Phase 1 Study of Tnb-486, a Novel CD19xCD3 T-Cell Engager, in Patients with Relapsed/Refractory (R/R) B-NHL

Jing-Zhou Hou, Ryan Jacobs, Seok-Goo Cho, Sumana Devata, Sameh Gaballa, Dok Hyun Yoon, Don A. Stevens, Jin Seok Kim, Ben Buelow, Ranjit Nair
Journal: Blood
Blood (2022) 140 (Supplement 1): 1474–1475.
https://doi.org/10.1182/blood-2022-166385
Published: 2022
Journal Articles

Safety and Efficacy of Cusatuzumab in Combination with Venetoclax and Azacitidine (CVA) in Patients with Previously Untreated Acute Myeloid Leukemia (AML) Who Are Not Eligible for Intensive Chemotherapy; An Open-Label, Multicenter, Phase 1b Study

Gail J. Roboz, Thomas Pabst, Ahmed Aribi, Joseph M. Brandwein, Hartmut Döhner, Walter Fiedler, Domenica Gandini, Michelle Geddes, Jing-Zhou Hou, Angela J. Howes, Anna Hultberg, Eric Huselton, Julie Jacobs, Colleen Kane, Ewa Lech-Marańda, Marieke Louwers, Kerri Nottage, Uwe Platzbecker, Raajit Rampal, Mariya Salman, Priya Shah, Don Stevens, Monic Stuart, Marion Subklewe, Anne Sumbul, Eunice S. Wang, Agnieszka Wierzbowska, Bin Yao, Karen Yee, Hagop Kantarjian, Gautam Borthakur
Journal: Blood
Blood (2021) 138 (Supplement 1): 369.
https://doi.org/10.1182/blood-2021-150371
Published: 2021
Journal Articles

Pretreatment Next-Generation Sequencing Is Associated with Response to Induction Chemotherapy in Patients Newly Diagnosed with Acute Myeloid Leukemia

Anastasia Tsagianni, MD, Konstantinos Lontos, MD, Mounzer Agha, MD, Anastasios Raptis, MD, Jing-Zhou Hou, MD PhD, Rafic J. Farah, MD, Robert L. Redner, MD, Annie Im, MD, Kathleen A. Dorritie, MD, Alison R. Sehgal, MD, James M. Rossetti, DO, Melissa Saul, MS, William Gooding, MS, Michael Boyiadzis, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 33–34.
https://doi.org/10.1182/blood-2020-138561
Published: 2020
Journal Articles

Dose Reductions and Discontinuations with Chronic Lymphocytic Leukemia (CLL) Patients Receiving Ibrutinib in Community and Academic Settings

Jing-Zhou Hou, MD PhD, Kellie Ryan, MPH, Senxi Du, Bruno S. Fang, MD, Stanley M. Marks, MD, Ray Page, Eileen Peng, PharmD, Keith Szymanski, Sharon Winters, Hannah Le, PharmD, MPH
Journal: Blood
Blood (2020) 136 (Supplement 1): 12–13.
https://doi.org/10.1182/blood-2020-139951
Published: 2020
Journal Articles

Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial

Clinical Trials & Observations
Andrew H. Wei, Pau Montesinos, Vladimir Ivanov, Courtney D. DiNardo, Jan Novak, Kamel Laribi, Inho Kim, Don A. Stevens, Walter Fiedler, Maria Pagoni, Olga Samoilova, Yu Hu, Achilles Anagnostopoulos, Julie Bergeron, Jing-Zhou Hou, Vidhya Murthy, Takahiro Yamauchi, Andrew McDonald, Brenda Chyla, Sathej Gopalakrishnan, Qi Jiang, Wellington Mendes, John Hayslip, Panayiotis Panayiotidis
Journal: Blood
Blood (2020) 135 (24): 2137–2145.
https://doi.org/10.1182/blood.2020004856
Published: 2020
Includes: Supplemental data
Journal Articles

Venetoclax with Low-Dose Cytarabine Induces Rapid, Deep, and Durable Responses in Previously Untreated Older Adults with AML Ineligible for Intensive Chemotherapy

Andrew Wei, MD, Stephen A. Strickland, MD, Jing-Zhou Hou, MD PhD, Walter Fiedler, MD, Tara L Lin, MD, Roland B. Walter, MDPhDMS, Anoop K Enjeti, MBBS,FRCPA,MDMRCP, Wan-Jen Hong, Brenda Chyla, Relja Popovic, PhD, Kaffa Fakouhi, Tu Xu, PhD, John Hayslip, Gail J. Roboz, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 284.
https://doi.org/10.1182/blood-2018-99-118729
Published: 2018
Journal Articles

Higher Number of Cycles of Cytarabine Consolidation Improves Outcomes in Elderly AML Patients

Asha Ricciuti, MD, Mounzer Agha, MD, Anastasios Raptis, MD, Jing-Zhou Hou, MD PhD, Rafic Farah, MD, Robert L. Redner, MD, Alison R. Sehgal, MD, Kathleen A. Dorritie, MD, James M. Rossetti, DO, Yongli Shuai, PhD, Daniel Normolle, PhD, Rahim Remtulla, MD, Shawn Tahata, MD, Michael Boyiadzis, MD, Annie Im, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 4000.
https://doi.org/10.1182/blood-2018-99-113935
Published: 2018
Journal Articles

Phase 1/2 Study of Venetoclax with Low-Dose Cytarabine in Treatment-Naive, Elderly Patients with Acute Myeloid Leukemia Unfit for Intensive Chemotherapy: 1-Year Outcomes

Andrew Wei, MBBS, PhD FRACP, FRCPA, Stephen A. Strickland, MD MSCI, Gail J. Roboz, MD, Jing-Zhou Hou, MD PhD, Walter Fiedler, MD, Tara L. Lin, MD, Roland B. Walter, MD PhD, Anoop Enjeti, MD MRCP, FRCPA, MClin Epid, GradCert Bioethics, Brenda Chyla, PhD, Relja Popovic, PhD, Kaffa Fakouhi, Pooja Shah, Martin Dunbar, DRPH, MS, Tu Xu, PhD, Mack Mabry, MD, John Hayslip, MD MSCR
Journal: Blood
Blood (2017) 130 (Supplement 1): 890.
https://doi.org/10.1182/blood.V130.Suppl_1.890.890
Published: 2017
Journal Articles

Phase 1 Clinical Trial of Adoptive Immunotherapy Using "Off-the-Shelf" Activated Natural Killer Cells (aNK) in Patients with Refractory/Relapsed Acute Myeloid Leukemia

Michael Boyiadzis, MD MHSc, Mounzer Agha, MD, Robert L Redner, MD, Alison Sehgal, MD, Annie Im, MD, Jing-Zhou Hou, Rafic Farah, MD, Kathleen A. Dorritie, MD, Anastasios Raptis, MD PhD, Seah H. Lim, MDPhDFRCP,FRCPath,MBBS, Hans Klingemann, MD PhD, Hong Wang, PhD, Natalia Lapteva, PhD, Mei Zhuyong, MD, Lisa H Butterfield, PhD, Cliona M. Rooney, PhD, Theresa L Whiteside, PhD
Journal: Blood
Blood (2016) 128 (22): 1649.
https://doi.org/10.1182/blood.V128.22.1649.1649
Published: 2016